MAb-normal – Rehabilitation Implications of Biologic Therapies for Cancer (824104)

Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies ("mAbs") used to treat patients with advanced malignancies improving overall survival. However, in unleashing the immune system there are risks for developing immune-related adverse events (irAEs), including numerous neuromusculoskeletal complications. These include: Guillain Barre syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, myositis, encephalitis and brachial plexus neuritis. As the use of ICPIs increases, it will be crucial for the rehabilitation team to be knowledgeable of the potential neuromusculoskeletal complications in order to properly identify and coordinate treatment for patients.
Will start with an introduction to the role of monoclonal antibodies. Potential neuromusculoskeletal complications and their clinical presentations will be highlighted with their unique characteristics. The session will close with a discussion of the role of the rehabilitation team in evaluation and treatment of these complications. Participants will learn the role of ICPIs, their neuromusculoskeletal complications and treatments to apply to their clinical practice.